The WNBA has officially removed marijuana from its prohibited substances list, marking a major shift in how the league handles cannabis use among players. The change comes through the long-form version of the league’s new Collective Bargaining Agreement with the Women’s National Basketball Players Association, a historic seven-year labor deal that begins with the 2026 season and runs through 2032. The policy update brings the WNBA closer in line with the NBA and other major sports leagues that have moved away from routine cannabis penalties as legalization spreads across the United States.
Under the previous WNBA policy, marijuana was included under “Drugs of Abuse,” and players could be tested for THC metabolites. First-time violations generally led to treatment referrals, while repeated violations could result in escalating consequences, including fines and suspensions. The new CBA removes marijuana from the prohibited substances list, signaling a shift away from treating cannabis use as an automatic disciplinary matter.
A Major Change in Player Drug Policy
The move follows months of labor negotiations between the WNBA and WNBPA. Earlier this year, reports indicated that the league had offered to eliminate marijuana testing as part of a broader package of player-focused reforms. That proposal has now become part of the finalized long-form agreement, according to reporting on the CBA language. The WNBA announced in March that the two sides had reached a tentative agreement, calling the new contract a transformational step for the league, and its press release archive later listed the completed long-form CBA as executed on May 22, 2026.
The cannabis provision is one piece of a much larger labor agreement that includes sweeping economic gains for players. The WNBA said the new deal includes the league’s first comprehensive revenue-sharing model, a salary cap increase from $1.5 million in 2025 to $7 million in 2026, and more than $1 billion in projected player salaries and benefits over the life of the agreement. Those economic terms have drawn much of the attention, but the drug-policy changes also represent an important update to player rights and wellness standards.
For years, cannabis advocates and athlete-wellness supporters argued that punishing professional athletes for marijuana use was increasingly out of step with state law, public opinion, and the lived reality of elite sports. WNBA players endure a demanding schedule, frequent travel, injury recovery, and high physical stress. The new policy does not frame marijuana as a performance-enhancing drug or as a substance that automatically triggers discipline simply because it appears in a test.
Marijuana Is Removed, But Not Completely Unregulated
The new policy does not mean marijuana use is entirely without limits. Players may still face cannabis-related testing or review under certain circumstances. According to Marijuana Moment’s review of the new CBA language, players could still be subject to testing if they enter the league’s Drugs of Abuse Program, are found to be under the influence while engaged in team or league activities, or have a dependency or other marijuana-related issue.
The agreement also includes consequences for players who are referred to marijuana treatment programs but fail to comply. Those players may face fines of $300 per day, and a player who shows a pattern of disregarding treatment responsibilities or who tests positive under those circumstances may face escalating penalties, including a $3,000 fine or suspension for at least three games. Players may also face reasonable-cause testing or administrative proceedings if they are convicted of a felony involving marijuana distribution.
That structure reflects a middle-ground approach. The WNBA is no longer treating cannabis as a routine banned substance, but it is preserving authority to act when marijuana use is tied to workplace impairment, dependency concerns, criminal distribution issues, or failure to follow treatment obligations. In practical terms, the change moves the league away from punishment for off-court cannabis use while maintaining rules around professional conduct and player health.
Hemp, CBD, and Cannabis Endorsement Rules
The new CBA also addresses how players can participate in cannabis-related business opportunities. That detail matters because modern athlete compensation extends far beyond league salary. Endorsements, investments, personal brands, wellness partnerships, and equity deals have become increasingly important parts of professional sports economics, especially as the WNBA enters a growth phase.
According to the new policy details reported by Marijuana Moment, the CBA lays out rules for player investment in and promotion of companies that sell marijuana and hemp-derived CBD products. This follows a broader trend in sports, where leagues are beginning to distinguish between THC-rich marijuana products, hemp-derived CBD, wellness products, and athlete endorsements.
For WNBA players, the change could create new commercial opportunities, particularly as women athletes build stronger personal brands and as cannabis and wellness companies seek credibility through sports partnerships. However, those opportunities are likely to come with restrictions, compliance requirements, and limitations designed to protect the league’s image and avoid conflicts with federal law, state law, team sponsors, and youth-facing marketing concerns.
Psychedelics and Synthetic Cannabinoids Added to Banned List
While the WNBA is loosening its marijuana rules, the new CBA also tightens restrictions on other substances. The updated prohibited substances list reportedly adds specific psychedelics, including DMT, ibogaine, psilocybin, and psilocin. It also prohibits synthetic cannabinoids, including delta-8 THC and related byproducts.
That combination shows the league is not broadly abandoning drug regulation. Instead, it is separating cannabis from substances it still views as unacceptable under the league’s drug policy. The distinction is important because cannabis reform in sports has often been framed as part of a wider reassessment of athlete wellness, pain management, and recovery. But leagues remain cautious about substances that may raise different safety, legal, or medical concerns.
The inclusion of synthetic cannabinoids is particularly notable because products such as delta-8 THC have occupied a legally complicated space in the hemp market. Unlike regulated cannabis sold through licensed state marijuana systems, many synthetic or semi-synthetic cannabinoid products have raised concerns about inconsistent testing, unclear potency, and uneven oversight. By keeping those substances prohibited, the WNBA appears to be limiting the policy change to marijuana while avoiding a broader opening for unregulated cannabinoid products.
Why the WNBA’s Cannabis Shift Matters
The WNBA’s decision is significant because the league had previously maintained a stricter cannabis policy than the NBA. The NBA removed marijuana from its prohibited substances list under its 2023 collective bargaining agreement, while the WNBA continued to list cannabis as a prohibited substance until the new 2026 CBA. Marijuana Moment described the prior WNBA policy as more restrictive than the NBA’s and several other professional leagues that had already reformed cannabis rules.
The change also reflects a broader cultural shift in sports. Cannabis is increasingly being discussed not only as a recreational substance, but also in relation to pain management, sleep, anxiety, inflammation, and recovery. That does not mean cannabis is risk-free or appropriate for every athlete, but it does mean leagues are moving away from older punishment-first models that treated marijuana use as inherently disqualifying.
For players, the policy may reduce anxiety around drug testing and allow more honest conversations with medical professionals. Athletes who use cannabis legally in their personal lives, or who are exploring it as part of recovery or wellness routines, may now face fewer automatic disciplinary risks. The change could also reduce the stigma around cannabis use in women’s professional sports, where player autonomy and health care have become increasingly important labor issues.
Part of a Transformational Labor Agreement
The marijuana-policy change is part of a much larger moment for the WNBA. The 2026 CBA arrives as the league enters its 30th season and experiences surging visibility, growing media attention, expansion momentum, and rising commercial interest. WNBA Commissioner Cathy Engelbert called the agreement a defining moment in the league’s history, while WNBPA Executive Director Terri Carmichael Jackson said the deal transforms the economics of the league. WNBPA President Nneka Ogwumike framed the agreement as a reflection of players owning their value and future alongside a growing league.
Against that backdrop, removing marijuana from the banned substances list is not an isolated reform. It fits into a broader labor philosophy that gives players more economic power, better benefits, and a stronger voice in the conditions of their work. Drug policy is part of workplace policy, and the WNBPA’s role in negotiating the CBA shows how cannabis reform can emerge through collective bargaining rather than legislative action alone.
The reform also underscores how athlete unions can influence drug policy in ways that reflect changing science, changing law, and changing player priorities. As more states legalize cannabis and as more athletes speak openly about recovery, mental health, and pain management, leagues are under increasing pressure to modernize rules that were written in a different cultural era.
A New Era for Cannabis and Women’s Basketball
The WNBA’s removal of marijuana from its banned substances list represents a meaningful step in the normalization of cannabis policy across professional sports. It does not create a free-for-all, and it does not eliminate the league’s ability to intervene when cannabis use is tied to impairment, dependency, treatment noncompliance, or criminal distribution. But it does end the automatic treatment of marijuana as a prohibited substance under the league’s standard drug policy.
For players, the change may bring more privacy, more flexibility, and fewer punitive consequences for legal cannabis use outside of basketball activities. For the league, it brings the WNBA closer to current norms in professional sports and reflects a more modern view of athlete wellness. For the cannabis industry, it opens the door to more nuanced partnerships, though within rules that still place limits on promotion and investment.
The policy shift is also symbolically important. Women’s basketball is growing rapidly, and the WNBA’s new CBA is being framed as one of the most important labor agreements in women’s professional sports. By including cannabis reform in that agreement, the league and players’ union are acknowledging that modern athlete policy is not just about salaries and schedules. It is also about health, autonomy, stigma, and the right to update outdated rules as the sports world evolves.
